New breast cancer treatment cuts the risk of recurrence in patients by 25% when added to standard hormone therapy, according to study
- The global study was led by scientists at Royal Marsden NHS Foundation Trust
- Patients received CDK 4/6 inhibitor abemaciclib with standard hormone therapy
- Phase three monarchE study found 25 per cent cut in recurrence of cancer
Patients with a common type of breast cancer have seen the risk of recurrence cut by a quarter following a new treatment, a study has shown.
During the global study, led by the Royal Marsden NHS Foundation Trust, 5,637 patients in 38 countries who had hormone receptor positive (HR+) early stage breast cancer and were a high risk of recurrence were chosen to take part.
Over two years, the phase three monarchE study found a 25 per cent reduction in recurrence of cancer when the CDK 4/6 inhibitor abemaciclib was added to the standard hormone therapy compared with hormone therapy alone.
The study has now been described as ‘one of the most promising breakthroughs for patients with this type of breast cancer in the last 20 years’, according to the institution.
Patients who had hormone receptor positive (HR+) early stage breast cancer and were a high risk of recurrence saw a 25 per cent reduction in recurrence of cancer when the CDK 4/6 inhibitor abemaciclib was added to their treatment. (Stock image)
In their study, the institution tested if patients taking the CDK 4/6 inhibitor abemaciclib along with hormone therapy following standard of care treatments such as chemotherapy, surgery and/or radiotherapy were at a reduced risk of recurrence compared with the standard hormone treatment alone.
Some 11.3 per cent of patients in the control group suffered a relapse of their cancer compared with 7.8 per cent of those in the abemaciclib group, Royal Marsden said.
Around 70 per cent of breast cancer patients have hormone receptor positive tumours, and a proportion of those have a higher risk of relapse in the first two years, it added.
‘Patients with disease that has spread to lymph nodes, a large tumour size at the time of diagnosis, or an increased cellular proliferation (determined by high grade of the tumour, or number of dividing cells) were considered to be at ‘high risk’ of recurrence and recruited to the study’ Royal Marsden said.
Study patient Sarah Ryder, 57, from Dorset, said she ‘did not feel much hope’ after finding out her cancer had spread to 23 lymph nodes when she was referred last year.
She said: ‘The trial has helped me believe in a future again. I can see my daughter grow up, go off to university next year and maybe have a family of her own one day.’
Professor Stephen Johnston, consultant medical oncologist at the Royal Marsden and professor of breast cancer medicine at the Institute of Cancer Research, said: ‘This research could potentially save many lives in the future.’
In their study, the institution tested if patients taking the CDK 4/6 inhibitor abemaciclib along with hormone therapy were at a reduced risk of recurrence. (Stock image)
He added: ‘The monarchE research has given us confidence that we will soon be able to offer our high risk HR+ patients a greater chance of keeping them cancer-free.
‘While there have been many advances in other early breast cancer subtypes such as HER2 positive disease, there has been no significant advancements for the large group of patients who have hormone receptor positive breast cancer since the late 1990s when aromatase inhibitors were introduced.
The results of the monarchE study are being presented at the European Society for Medical Oncology Virtual Congress on Sunday evening and simultaneously published in the Journal of Clinical Oncology.
The monarchE trial was funded by Eli Lilly pharmaceutical.
Source: Read Full Article